Kgn Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 24 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -29.79%
- Profit Growth 15.97%
- Ebitda 10.45%
- Net Worth 23.77%
- Total Assets -16.71%
About Kgn Pharmaceuticals
Kgn Pharmaceuticals Private Limited (KPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 08 August 2000 and has a history of 24 years and six months. Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Kgn Pharamaceuticals Priate Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mohammed Ansari, Khursheed Ansari, Mohammed Ansari, and One other member serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24239MH2000PTC128154
- Company No.
128154
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Aug 2000
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Kgn Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohammed Ansari  | Director | 01-Dec-2014 | Current |
| Khursheed Ansari | Director | 12-Aug-2002 | Current |
| Mohammed Ansari | Director | 27-Feb-2018 | Current |
| Pradeep Patil | Whole-Time Director | 30-Sep-2015 | Current |
Financial Performance of Kgn Pharmaceuticals.
Kgn Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 29.79% decrease. The company also saw a substantial improvement in profitability, with a 15.97% increase in profit. The company's net worth Soared by an impressive increase of 23.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kgn Pharmaceuticals?
In 2022, Kgn Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kgn Pharmaceuticals?
Kgn Pharmaceuticals has a workforce of 31 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kgn Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kgn Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
